Related Experiment Video

Updated: Oct 9, 2025

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
10:29

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

10.7K

Small-Cell Lung Cancer Long-Term Survivor Patients: How to Find a Needle in a Haystack?

Andrea Plaja1, Teresa Moran1, Enric Carcereny1

  • 1Catalan Institute of Oncology (ICO)-Badalona, Badalona-Applied Research Group in Oncology (B-ARGO), Medical Oncology Department, 08916 Badalona, Spain.

International Journal of Molecular Sciences
|December 24, 2021
PubMed

Insights

Small-cell lung cancer (SCLC) remains aggressive with limited treatment options. This review explores SCLC biology, the tumor microenvironment, and biomarkers to improve patient outcomes and identify new therapeutic vulnerabilities.

Area of Science:

  • Oncology
  • Cancer Biology
  • Translational Research

Background:

  • Small-cell lung cancer (SCLC) is an aggressive malignancy with poor treatment outcomes.
  • Limited progress in SCLC therapies is attributed to universal TP53/RB1 inactivation and lack of targetable oncogenes.
  • The immunosuppressive tumor microenvironment hinders immune checkpoint inhibitor (ICI) efficacy.

Purpose of the Study:

  • To review SCLC biology and molecular classification.
  • To examine the SCLC tumor microenvironment and challenges in predictive biomarker development.
  • To assess characteristics of long-term SCLC survivors for prognostic factors and treatment vulnerabilities.

Main Methods:

  • Literature review of SCLC biology, classification, and treatment resistance.
  • Analysis of tumor microenvironment and its impact on therapy.
  • Evaluation of clinical and molecular data from long-term SCLC survivors.

Main Results:

  • SCLC exhibits unique biology with universal TP53/RB1 inactivation, complicating targeted therapy development.
  • Current first-line treatments (atezolizumab/durvalumab + chemotherapy) offer modest survival benefits.
  • Lack of predictive biomarkers limits personalized treatment strategies.

Conclusions:

  • Understanding SCLC molecular subtypes and tumor microenvironment is crucial for novel therapeutic strategies.
  • Identifying biomarkers for ICI response and characterizing long-term survivors may reveal new vulnerabilities.
  • Further research is needed to overcome treatment resistance and improve survival in SCLC patients.
Keywords:
PD-L1immunotherapylong-term survivorsmolecular subtypespredictive biomarkersprognostic factorssmall-cell lung cancertumor microenvironment

More Related Videos

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

10.6K
Isolation and Characterization of a Head and Neck Squamous Cell Carcinoma Subpopulation Having Stem Cell Characteristics11:28

Isolation and Characterization of a Head and Neck Squamous Cell Carcinoma Subpopulation Having Stem Cell Characteristics

Published on: May 11, 2016

8.6K

Related Concept Videos

Cancer Survival Analysis01:21

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
478
Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
5.1K
Assumptions of Survival Analysis01:15

Assumptions of Survival Analysis

Survival models analyze the time until one or more events occur, such as death in biological organisms or failure in mechanical systems. These models are widely used across fields like medicine, biology, engineering, and public health to study time-to-event phenomena. To ensure accurate results, survival analysis relies on key assumptions and careful study design.
215
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
6.0K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K